MarginsXMarginsX
Home › Markets › Health Care › FBIO

Fortress Biotech Inc. (FBIO)

FBIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.71
-9.04% on the day
Market cap
$57.7M
Micro cap
Revenue · 2025
$63.3M
+9.7% on 2024
Net income · 2025
$6.8M
10.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1429260/000110465926037874/0001104659-26-037874-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerFBIO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001429260
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$63.3M
Net income$6.8M
Operating income-$70.2M
Net margin10.8%
Operating margin-111.0%
Revenue growth+9.7%
Cash$79.4M
Total assets$185.5M
P/E (computed)8.5×
P/S (computed)0.9×

Warning signs

Cash runway
Cash-flow positive
$196.6M cash at June 30, 2026
Share count, 1 year
+8.7%
2025-10-31 to 2026-11-10
Going-concern doubt
No
10-Q filed November 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-13
Cash and burn$196.6M cash; operating cash flow $31.5M a quarter.Report 2026-06-30
Shares outstanding33,742,297 (2026-11-10); 31,037,937 a year earlier.Cover page 2026-11-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, New York, New York, United StatesPCAOB Form AP 2026-04-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$18.7M-$468K-$59.3M$196.6M$35.0M$68.5M10-Q 2026-08-13
Q1 2026
2026-03-31
$16.0M$110.4M$203.9M$255.8M$37.5M$66.2M10-Q 2026-05-14
Q4 2025
2025-12-31
$16.1M-$3.9M-$12.5M$79.4M$54.5M$63.3M10-K 2026-03-31
Q3 2025
2025-09-30
$17.6M$5.8M-$6.1M$86.2M$47.8M$62.3M10-Q 2025-11-14
Q2 2025
2025-06-30
$16.4M$15.5M-$27.6M$74.4M$50.0M$59.3M10-Q 2026-08-13
Q1 2025
2025-03-31
$13.1M-$10.6M-$19.6M$91.3M$56.4M$57.8M10-Q 2026-05-14
Q4 2024
2024-12-31
$15.1M-$6.8M-$12.9M$57.3M$58.0M$57.7M10-K 2026-03-31
Q3 2024
2024-09-30
$14.6M-$12.9M-$20.1M$58.9M$52.5M$62.5M10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32025-12-18
Latest annual report10-K2026-03-31
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-13
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 888 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.6%
1 month-3.6%
3 months-36.9%
Year to date-48.6%
1 year-24.5%
From 52-week high-57.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
FBIOPFortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock$13.86

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BOLDBoundless Bio Inc.$2.41-3.60%$56.9M
XBITXBiotech Inc.$1.85-5.37%$56.4M
TNXPTonix Pharmaceuticals Holding Corp.$2.88-4.32%$56.0M
SPROSpero Therapeutics Inc.$0.9464-5.35%$55.1M
LFVNLifevantage Corporation Common Stock (Delaware)$4.77-4.02%$60.5M
VRCAVerrica Pharmaceuticals Inc.$3.20-10.11%$55.0M
CINGCingulate Inc.$3.75-12.79%$54.5M
INCRIntercure Ltd.$3.63-4.22%$54.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier